# Electrochemotherapy in head and neck cancer patients

Published: 17-01-2011 Last updated: 30-11-2024

The primary objective of this study is to determine the response rate of electrochemotherapy in head and neck cancer. Secondary objectives are to monitor local and systemic side effects and adverse events and to determine quality of life before and...

Ethical review	Approved WMO
Status	Completed
Health condition type	Respiratory and mediastinal neoplasms malignant and unspecified
Study type	Interventional

# Summary

### ID

NL-OMON36446

**Source** ToetsingOnline

**Brief title** Electrochemotherapy in head and neck cancer patients

# Condition

- Respiratory and mediastinal neoplasms malignant and unspecified
- · Head and neck therapeutic procedures

Synonym head and neck cancer

**Research involving** Human

# **Sponsors and support**

**Primary sponsor:** Vrije Universiteit Medisch Centrum **Source(s) of monetary or material Support:** Ministerie van OC&W

## Intervention

Keyword: electroporation, head and neck cancer

## **Outcome measures**

#### **Primary outcome**

Treatment response

#### Secondary outcome

Adverse effects and serious adverse events and quality of life

# **Study description**

#### **Background summary**

Na eerdere behandelingen in het hoofd-halsgebied kunnen bij de behandeling van een nieuwe/recidu/recidief tumor geen reguliere therapeutische opties meer voorhanden zijn. Electrochemotherapie is een relatief nieuwe behandelingsmodaliteit die soms nog wel mogelijk is.

#### **Study objective**

The primary objective of this study is to determine the response rate of electrochemotherapy in head and neck cancer. Secondary objectives are to monitor local and systemic side effects and adverse events and to determine quality of life before and after electrochemotherapy

#### Study design

Prospective, monocenter open-label study of 10 patients to define the treatment response of electrochemotherapy in end-stage head and neck cancer patients.

#### Intervention

Intratumoral or intraveneous application of bleomycin fllowed by electroporation in which an applicator with needle electrodes are repeatedly applied to the entire tumor with margins.

#### Study burden and risks

Burden to the patient consist of hospital admission and treatment under general anesthesia. Risks are related to reported adverse effects, e.g. pain, bleeding, oedema and necrosis.

# Contacts

#### Public

Vrije Universiteit Medisch Centrum

De Boelelaan 1117 1081 HV NL **Scientific** Vrije Universiteit Medisch Centrum

De Boelelaan 1117 1081 HV NL

# **Trial sites**

# **Listed location countries**

Netherlands

# **Eligibility criteria**

Age Adults (18-64 years) Elderly (65 years and older)

## **Inclusion criteria**

Biopsy confirmed malignancy of mucosa or skin Accessibility of the entire tumor (with 0.5 cm margins) for the applicator with electrode array all directions Creatinine level < 150  $\mu$ mol/l

# **Exclusion criteria**

Tumors that involve a 50% or greater encasement of a blood vessel as measured by MRI or CT scan Tumors having bone invasion Hypersensitivity to Bleomycin Subjects who have received or will exceed a total lifetime dose of Bleomycin greater than 400.000 IUg/m2 Subjects deemed unsuitable for general anesthesia and local anesthesia is not possible. Subjects with pulmonary fibrosis. Subjects with indwelling cardiac pacemakers who cannot tolerate a period with pacemaker turned off Subjects with a history of uncontrolled cardiac arrhythmia Women who are pregnant, or are nursing

# Study design

## Design

Study type: Interventional	
Masking:	Open (masking not used)
Control:	Uncontrolled
Primary purpose:	Treatment

## Recruitment

NL	
Recruitment status:	Completed
Start date (anticipated):	01-05-2011
Enrollment:	10
Туре:	Actual

## Medical products/devices used

Generic name:	electroporation equipment Cliniporator
Registration:	Yes - CE intended use

# **Ethics review**

Approved WMODate:17-Application type:FirstReview commission:ME

17-01-2011 First submission METC Amsterdam UMC

# **Study registrations**

# Followed up by the following (possibly more current) registration

No registrations found.

## Other (possibly less up-to-date) registrations in this register

No registrations found.

# In other registers

**Register** CCMO ID NL34661.029.10